Shares of OKYO Pharma Limited (NASDAQ:OKYO – Get Free Report) shot up 1.7% on Monday . The company traded as high as $1.22 and last traded at $1.18. 77,758 shares were traded during mid-day trading, a decline of 32% from the average session volume of 114,929 shares. The stock had previously closed at $1.16.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of OKYO Pharma in a research note on Thursday, October 24th.
Get Our Latest Stock Report on OKYO Pharma
OKYO Pharma Price Performance
OKYO Pharma Company Profile
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Read More
- Five stocks we like better than OKYO Pharma
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Must-Hold Stocks with Double-Digit Upside for 2025
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Micron: Why Now Is the Time to Be Brave
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
